Prevagen ‘Improves Memory’ Claims Will Be Qualified Under Class Action Settlement
Executive Summary
Quincy Bioscience doesn’t admit to “any liability or wrongdoing of any kind associated with the claims alleged” in settlement to complaint in federal court in Florida, but agrees to pay plaintiffs refunds of 30% of the MSRP for its supplements, up to $70 per individual claimant.
You may also be interested in...
Memory Health Marketer Reminded About Brain Health Ad Claims Substantiation In NAD Review
Michigan firm likely remembered burden for substantiating health as well as structure/function claims under FDA regulations for supplements after NAD reviewed its ad materials presented online, in videos and in news releases submitted by Vision Elements.
FTC’s Monetary Relief Claims Dismissed In Prevagen Fraud Case; Supreme Court Decision Cited
The Federal Trade Commission’s claim for monetary relief against the Prevagen memory supplement marketer is dismissed by a federal judge in New York, who cites recent Supreme Court decision gutting the agency's long-favored mechanism for collecting monetary penalties under the FTC Act.
‘Clinically Proven’ Claim Leaving RB's Brain Health Supplements In US Class Action Settlement
Settlement in Southern District of Florida federal court includes a consolidated class action complaint against UK firm’s US businesses comprising cases in Florida, New York and California – filed in 2020 over statements the products were “clinically proven” to improve “brain performance” including focus, memory, learning, accuracy, concentration and reasoning.